Proton therapy for adult-type diffuse glioma: a systematic review
A partir d'une revue systématique de la littérature publiée jusqu'en 2023 (12 études, 810 patients), cette étude analyse la survie et les toxicités associées à une protonthérapie pour un gliome diffus
Background: We conducted a systematic review to evaluate outcomes and toxicities associated with proton therapy in the treatment of adult-type diffuse glioma.
Methods: Following PRISMA guidelines, we searched PubMed for both prospective and retrospective studies on proton therapy for adult diffuse gliomas, including low-grade gliomas and glioblastomas. Survival and toxicity outcomes were reported separately for these glioma types.
Results: Twelve studies from 2013 to 2023 were selected, comprising 3 prospective and 9 retrospective studies. The analysis covered 570 patients with low-grade gliomas and 240 patients with glioblastoma or WHO grade 4 gliomas. Proton therapy was found to be comparable to conventional radiotherapy in terms of survival outcomes. Its main advantage is the ability to minimize radiation exposure to healthy tissues.
Discussion: Proton therapy offers comparable survival outcomes to conventional radiotherapy for adult diffuse gliomas and may enhance treatment tolerance, especially regarding neurocognitive function. A major limitation of this review is the predominance of retrospective studies. Future research should ensure rigorous patient selection and adhere to the latest WHO 2021 classification
Critical Reviews in Oncology/Hematology , article en libre accès, 2024